Growth Metrics

ClearPoint Neuro (CLPT) Common Equity (2017 - 2026)

ClearPoint Neuro's Common Equity history spans 14 years, with the latest figure at $28.0 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 10.36% to $28.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $28.0 million, a 10.36% increase, with the full-year FY2025 number at $28.0 million, up 10.36% from a year prior.
  • Common Equity hit $28.0 million in Q4 2025 for ClearPoint Neuro, up from $15.9 million in the prior quarter.
  • Over the last five years, Common Equity for CLPT hit a ceiling of $48.8 million in Q4 2021 and a floor of $15.9 million in Q3 2025.
  • Historically, Common Equity has averaged $33.0 million across 5 years, with a median of $32.4 million in 2023.
  • Biggest five-year swings in Common Equity: skyrocketed 29510.74% in 2021 and later tumbled 45.26% in 2025.
  • Tracing CLPT's Common Equity over 5 years: stood at $48.8 million in 2021, then dropped by 24.39% to $36.9 million in 2022, then tumbled by 42.6% to $21.2 million in 2023, then grew by 19.91% to $25.4 million in 2024, then increased by 10.36% to $28.0 million in 2025.
  • Business Quant data shows Common Equity for CLPT at $28.0 million in Q4 2025, $15.9 million in Q3 2025, and $19.7 million in Q2 2025.